Click on an item below to open a detailed WORD document:

PR018: February 2008
CAMBRIDGE BIOSTABILITY AWARDED £200,000 EEDA GRANT TO DEVELOP NOVEL STABLE VACCINE DELIVERY PLATFORM

PR017: 23rd November 2007
CAMBRIDGE BIOSTABILITY APPOINTS LUCA GUERZONI AS CHIEF EXECUTIVE OFFICER

PR016: 31st May 2007
ACE BIOSCIENCES IN-LICENCES PHASE I ENTEROTOXIGENIC E COLI (ETEC) VACCINE FROM CAMBRIDGE BIOSTABILITY LTD

PR015: December 2006
CBL AND PANACEA BIOTECH INDIA SIGN JOINT VENTURE AGREEMENT
Under the terms of the JV, Panacea Biotec has taken a 10% stake in Cambridge Biostability, for a total consideration of £1.935m.

PR014: October 2006
JOHN LAMBERT APPOINTED CHAIRMAN
John will take over the role from David Stone, who is currently Chairman and Chief Executive Officer.

PR013: October 2006
CBL REACHES NEW STABLE BOTULINUM VACCINE MILESTONE
Cambridge Biostability and DVC LLC, a CSC company, announce results of first stage testing

PR012: March 2006
STABLE VACCINES OFFER AN END TO BOOSTERS
DTI funds controlled release vaccine technology to reduce cost and improve
Effectiveness of vaccine programmes

PR011: December 2005
CAMBRIDGE BIOSTABILITY INVESTS £1M IN COMMERCIAL SPRAY DRYER
World’s first vaccine spray drier to reduce time to market on childhood vaccine

PR009: 30 June 2005
TO ‘MAKE POVERTY HISTORY’ MUST ADDRESS VACCINATION WASTAGE RADICAL NEW APPROACH NEEDED TO REDUCE GLOBAL THREAT OF DISEASE

PR008: 1st August 2005
CAMBRIDGE BIOSTABILITY APPOINTS JOHN LAMBERT AS NON-EXECUTIVE DIRECTOR

PR006: May 2005
STABLE VACCINE CO. BRINGS NEW HOPE TO DIARRHOEA SUFFERERS
Cambridge Biostability to licence Acambis HolaVax-ETEC vaccine

PR004: February 2005
US GOVERNMENT FUNDS NEW STABLE VACCINE FORMULATION DEVELOPMENT FOR PROTECTION AGAINST BOTULISM

PR003: December 2004
CAMBRIDGE SCIENTIST NOMINATED ‘GREAT BRITON 2004’
Dr Bruce Roser, developer of ‘sugar vaccine’, in top 8 of British scientists

PR002: 19th OCTOBER 2004
DFID BOOST FOR NEW VACCINE TECHNOLOGY WHICH COULD PROTECT 10 MILLION MORE CHILDREN FROM KILLER DISEASES WITHIN EXISTING BUDGETS
Panacea Biotec collaborates with Cambridge Biostability

PR001: 19TH OCTOBER 2004
10 MILLION MORE CHILDREN COULD BE PROTECTED FROM KILLER DISEASES WITHIN EXISTING BUDGETS
A new technology based on processes two billion years old promises to revolutionise the international vaccine programme - enabling children, even in remote areas, to receive cheaper and safer immunisation from preventable killer diseases.

Cambridge Biostability Limited is a limited company registered in England & Wales with registered number 003630055 and having its registered office at Unit 184, Cambridge Science Park, Milton Road, Cambridge, CB4 0GA, UK.